Skip to main content

Table 6 NFκB binding sites confirmed by chromatin immunoprecipitation.

From: Phosphatidylinositol 3-kinase signaling in proliferating cells maintains an anti-apoptotic transcriptional program mediated by inhibition of FOXO and non-canonical activation of NFκB transcription factors

Gene

Binding site position

TRANSFAC 8.4

TRANSFAC 11.1

Primer Position

AMIGO2

-721

 

V$NFKAPPAB_01

-795

BDNF

-223

V$CREL_01

V$NFKAPPAB_01

-586

BIRC3/cIAP2

-92

V$CREL_01

 

-75

 

-115

 

V$NFKAPPAB65_01

 
 

-178

V$NFKAPPAB65_01

V$NFKAPPAB_01

 

CCL2

-2602

V$NFKAPPAB65_01

V$NFKAPPAB_01

-2763

 

-2631

V$NFKAPPAB_01

V$NFKAPPAB_01

 
 

-2804

V$CREL_01

V$NFKAPPAB_01

 

CCND1

-698

V$CREL_01

 

-701

EDN1

-225 (II)

V$CREL_01

 

-241

 

-293 (II)

V$CREL_01

  
 

-2263 (I)

V$CREL_01

 

-2252

F3

-188 (II)

V$NFKAPPAB65_01

V$CREL_01

-351

 

-482 (II)

V$CREL_01

V$NFKAPPAB_01

 
 

-2373 (I)

V$NFKAPPAB65_01

V$NFKAPPAB_01

-2358

FST

-1335

V$CREL_01

 

-1341

GABPB2

-13

V$CREL_01

 

-145

G0S2

-1832

V$CREL_01

 

-1914

IGFBP5

-176

 

V$NFKAPPAB_01

-135

IL7R

-184 (II)

 

V$NFKB_C

-184

 

-2348 (I)

V$NFKAPPAB65_01

V$NFKAPPAB_01

-2344

MAT2A

-343 (II)

 

V$NFKAPPAB_01

-312

 

-1249 (I)

V$CREL_01

 

-1248

PLAU

-1598

V$CREL_01

 

-1942

 

-1838

 

V$NFKAPPAB65_01

 
 

-1872

V$NFKAPPAB65_01

V$NFKAPPAB_01

 

PTX3

-64

V$NFKAPPAB_01

V$NFKAPPAB_01

-147

RGS20

-179

 

V$NFKAPPAB_01

-345

STC2

-642

 

V$NFKAPPAB65_01

-587

TNFRSF11B/osteoprotegerin

-128

V$CREL_01

 

-258

  1. The predicted NFκB binding sites that were confirmed by chromatin immunoprecipitation are indicated by the most 5' nucleotide. When multiple matrices predicted overlapping sites, the position indicates the most 5' nucleotide of the consensus sequence (see Additional file 4 for all sequences). Both over-represented (Table 4) and 7 additional (Additional file 4) NFκB matrices were used for the predictions. The TRANSFAC matrices shown are those that predicted the indicated sites with the lowest p-values. ChIP assays were considered to confirm binding sites located within 500 bp of the primer position. The site in the promoter region of GABPB2 was predicted using the alignment of the hg17 and mm5 genomes. Multiple binding sites for a gene are designated I and II, where appropriate. Primer positions are indicated by the most 5' nucleotide of the forward primer; all amplicons were 50–55 bp.